| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1182/BLOOD-2016-05-712828 |
| P698 | PubMed publication ID | 27247135 |
| P50 | author | Deborah Siegal | Q80481758 |
| P2093 | author name string | Darryl P Leong | |
| Jeff S Healey | |||
| Graeme Fraser | |||
| François Caron | |||
| Christopher Hillis | |||
| Annie Duan | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| Atrial Fibrillation | Q815819 | ||
| systematic review | Q1504425 | ||
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 138-140 | |
| P577 | publication date | 2016-05-31 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis | |
| P478 | volume | 128 |
| Q39227773 | Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia |
| Q90777008 | Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia |
| Q58554222 | Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms |
| Q90189084 | Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation |
| Q99578679 | Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration |
| Q39383524 | Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management |
| Q38944823 | Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies |
| Q50121608 | Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. |
| Q45073137 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. |
| Q38656503 | Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials |
| Q87869046 | Chronic lymphocytic leukaemia |
| Q92276384 | Complications and management of coagulation disorders in leukemia patients |
| Q89777331 | Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib |
| Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
| Q89776907 | Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis |
| Q90960485 | Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases |
| Q96690257 | Direct Oral Anticoagulants In Patients With Hematologic Malignancies |
| Q50166015 | Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. |
| Q92980807 | Electrophysiologic Complications in Cancer Patients |
| Q52592617 | Electrophysiologic Toxicity of Chemoradiation. |
| Q92969005 | Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation |
| Q92550867 | High incidence of atrial fibrillation in patients treated with ibrutinib |
| Q90465435 | Hypertension and incident cardiovascular events following ibrutinib initiation |
| Q64091347 | Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes |
| Q64120393 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL |
| Q47780043 | Ibrutinib and its use in the treatment of chronic lymphocytic leukemia |
| Q64261109 | Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis |
| Q90534414 | Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes |
| Q38969861 | Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies |
| Q61796907 | Ibrutinib-induced cardiomyopathy |
| Q42368314 | Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach |
| Q52592631 | Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. |
| Q34553880 | New developments in the management of Waldenström macroglobulinemia |
| Q47582687 | Optimizing frontline therapy of CLL based on clinical and biological factors. |
| Q39306435 | Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. |
| Q54976521 | Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. |
| Q47548582 | Profound Sinoatrial Arrest Associated with Ibrutinib |
| Q92355034 | Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis |
| Q92630079 | Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk |
| Q99549141 | Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review |
| Q49989091 | Safety profiles of novel agent therapies in CLL. |
| Q38654101 | Targeting B Cell Signaling in Chronic Lymphocytic Leukemia |
| Q54979102 | Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome. |
| Q54977449 | Targeting the B cell receptor pathway in non-Hodgkin lymphoma. |
| Q57471770 | Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q90156412 | Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib |
| Q48211381 | Ventricular arrhythmias and sudden death in patients taking ibrutinib |
| Q90575544 | What is new in the treatment of Waldenstrom macroglobulinemia? |
Search more.